IL182225A - Nucleic acid compound encoding altered glycoprotein filvirus, DNA plasmid, recombinant virus or adenovirus containing the compound, a modified viral glycoprotein glycoprotein, vaccine or vaccine containing the compound or the glycoprotein alveolar compound and the glycoprotein - Google Patents

Nucleic acid compound encoding altered glycoprotein filvirus, DNA plasmid, recombinant virus or adenovirus containing the compound, a modified viral glycoprotein glycoprotein, vaccine or vaccine containing the compound or the glycoprotein alveolar compound and the glycoprotein

Info

Publication number
IL182225A
IL182225A IL182225A IL18222507A IL182225A IL 182225 A IL182225 A IL 182225A IL 182225 A IL182225 A IL 182225A IL 18222507 A IL18222507 A IL 18222507A IL 182225 A IL182225 A IL 182225A
Authority
IL
Israel
Prior art keywords
molecule
nucleic acid
modified filovirus
acid molecule
modified
Prior art date
Application number
IL182225A
Other languages
English (en)
Hebrew (he)
Other versions
IL182225A0 (en
Original Assignee
Us Gov Health & Human Serv
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Crucell Holland Bv filed Critical Us Gov Health & Human Serv
Publication of IL182225A0 publication Critical patent/IL182225A0/en
Publication of IL182225A publication Critical patent/IL182225A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL182225A 2004-09-27 2007-03-27 Nucleic acid compound encoding altered glycoprotein filvirus, DNA plasmid, recombinant virus or adenovirus containing the compound, a modified viral glycoprotein glycoprotein, vaccine or vaccine containing the compound or the glycoprotein alveolar compound and the glycoprotein IL182225A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61388304P 2004-09-27 2004-09-27
US67760605P 2005-05-03 2005-05-03
US67976705P 2005-05-10 2005-05-10
US70169405P 2005-07-22 2005-07-22
US71587405P 2005-09-09 2005-09-09
PCT/US2005/034798 WO2006037038A1 (en) 2004-09-27 2005-09-27 Optimized vaccines to provide protection against ebola and other viruses

Publications (2)

Publication Number Publication Date
IL182225A0 IL182225A0 (en) 2007-09-20
IL182225A true IL182225A (en) 2015-07-30

Family

ID=35695786

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182225A IL182225A (en) 2004-09-27 2007-03-27 Nucleic acid compound encoding altered glycoprotein filvirus, DNA plasmid, recombinant virus or adenovirus containing the compound, a modified viral glycoprotein glycoprotein, vaccine or vaccine containing the compound or the glycoprotein alveolar compound and the glycoprotein

Country Status (7)

Country Link
US (2) US8101739B2 (enExample)
EP (1) EP1797113B1 (enExample)
JP (1) JP5046941B2 (enExample)
AU (1) AU2005289439B2 (enExample)
CA (1) CA2581840C (enExample)
IL (1) IL182225A (enExample)
WO (1) WO2006037038A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
US7947286B2 (en) 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
JP5670330B2 (ja) * 2008-08-07 2015-02-18 ハー マジェスティ ザ クイーン イン ライト オブ カナダ アズ リプリゼンテド バイ ザ ミニスター オブ ヘルスＨＥＲ ＭＡＪＥＳＴＹ ＴＨＥ ＱＵＥＥＮ ＩＮ ＲＩＧＨＴＯＦ ＣＡＮＡＤＡ ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ＴＨＥ ＭＩＮＩＳＴＥＲ ＯＦ ＨＥＡＬＴＨ 最適化したプロモーター配列
EP3466440A1 (en) 2010-04-16 2019-04-10 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Chimpanzee adenoviral vector-based filovirus vaccines
ES2676196T3 (es) * 2010-12-14 2018-07-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vacunas contra filovirus de adenovirus de serotipo 25 y serotipo 35
DK2764565T3 (da) 2011-10-05 2023-04-17 Oned Mat Inc Aktive siliciumnanostrukturmaterialer til lithiumionbatterier og fremgangsmåder, sammensætninger, komponenter og anordninger i forbindelser dermed
JP6389163B2 (ja) 2012-04-12 2018-09-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
CA2901501C (en) * 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
SG11201610446XA (en) 2014-06-26 2017-01-27 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
NZ730511A (en) 2014-09-03 2022-04-29 Janssen Vaccines & Prevention Bv Methods and compositions for inducing protective immunity against filovirus infection
KR20190062617A (ko) 2014-09-03 2019-06-05 버베리안 노딕 에이/에스 면역 반응을 증대시키기 위한 방법 및 조성물
SG11201701506PA (en) * 2014-09-03 2017-03-30 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
US20170326225A1 (en) * 2014-12-16 2017-11-16 Curevac Ag Ebolavirus and marburgvirus vaccines
GB201502209D0 (en) 2015-02-10 2015-03-25 Sec Dep For Health The And Chancellor Masters And Scholars Of The University Of Oxford The And Micro Filovirus therapy
CA2977499C (en) * 2015-02-25 2023-10-03 Vanderbilt University Antibody-mediated neutralization of marburg virus
US11135280B2 (en) * 2016-03-28 2021-10-05 Integrated Biotherapeutics, Inc. Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP3484505A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP3606553A1 (en) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
CA3107083A1 (en) * 2018-08-13 2020-02-20 Janssen Vaccines & Prevention B.V. Stabilized filovirus glycoprotein trimers
WO2022226060A1 (en) * 2021-04-21 2022-10-27 Vanderbilt University Antibody cocktail for treatment of ebolavirus infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
WO1999032147A1 (en) * 1997-12-23 1999-07-01 The Regents Of The University Of Michigan Immunization for ebola virus infection
JP2005508916A (ja) * 2001-10-01 2005-04-07 アメリカ合衆国 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発
WO2003092582A2 (en) * 2002-04-30 2003-11-13 The Trustees Of The University Of Pennsylvania Chimeric ebola virus envelopes and uses therefor

Also Published As

Publication number Publication date
US20120156239A1 (en) 2012-06-21
EP1797113B1 (en) 2014-11-26
AU2005289439B2 (en) 2011-12-01
IL182225A0 (en) 2007-09-20
JP5046941B2 (ja) 2012-10-10
US9012618B2 (en) 2015-04-21
WO2006037038A9 (en) 2006-05-26
WO2006037038A1 (en) 2006-04-06
AU2005289439A1 (en) 2006-04-06
US8101739B2 (en) 2012-01-24
CA2581840A1 (en) 2006-04-06
JP2008514203A (ja) 2008-05-08
WO2006037038B1 (en) 2006-08-03
EP1797113A1 (en) 2007-06-20
CA2581840C (en) 2014-08-05
US20090232841A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
IL182225A (en) Nucleic acid compound encoding altered glycoprotein filvirus, DNA plasmid, recombinant virus or adenovirus containing the compound, a modified viral glycoprotein glycoprotein, vaccine or vaccine containing the compound or the glycoprotein alveolar compound and the glycoprotein
WO2009124312A3 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
IL171831A (en) Recombinant influenza virus preparation, influenza virus method, and method of gene delivery tool
WO2008115199A3 (en) Chimeric virus vaccines
WO2008108890A3 (en) Conditionally replicating viruses for cancer therapy
WO2007118206A3 (en) Canine influenza virus
WO2010039224A3 (en) Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
PL1951882T3 (pl) Kwasy nukleinowe kodujące szczepionkę przeciwko wirusowi wywołującemu zespół zaburzeń reprodukcyjnych i oddechowych u świń
GB2451216B (en) A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein
WO2007062656A3 (en) A nucleotide vaccine
WO2005035556A3 (en) Sars-coronavirus virus-like particles and methods of use
WO2005025614A3 (en) Improvements in vaccination
WO2006115843A3 (en) Nipah virus vaccines
EP2527445A3 (en) Treatment and prevention of influenza
EE200300100A (et) Polüpeptiid, selle kodeerivat nukleotiidjärjestust sisaldav nukleiinhape, vektor ja peremeesrakk, meetod polüpeptiidi valmistamiseks ning farmatseutiline kompositsioon
WO2005035712A3 (en) Methods and compositions for infectious cdna of sars coronavirus
EP1989316A4 (en) METHOD FOR THE PRODUCTION OF RECOMBINANT VIRUS, DNA CONSTRUCTS, RECOMBINANT VIRUS AND VACCINE COMPOSITIONS
WO2005042566A3 (en) Antiangiogenicpeptides for treating or preventing endometriosis
WO2003031569A3 (en) Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
NO20076452L (no) cDNA construct of Salmonidae alphavirus
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof
WO2003006654A3 (en) Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
WO2006047728A3 (en) Bmp gene and fusion protein
WO2007022195A3 (en) Nitrate transport components

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed